高级检索
当前位置: 首页 > 详情页

Study on anti-inflammatory effect of peptides-conjugated alumina nanoparticle on allergic rhinitis mice model

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China. [2]Department of Otorhinolaryngological, Dezhou Second People's Hospital, Dezhou, China. [3]Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. [4]Department of Otolaryngology Division I, The First Affiliated Hospital of Kunming Medical University, Kunming, China
出处:
ISSN:

关键词: Allergy Nanoparticle Peptide Rhinitis

摘要:
Allergic rhinitis (AR) is a common atopic problem in which immune response to the environmental factors leads to clinical symptoms. Helicobacter pylori neutrophil-activating protein (HP-NAP) as a peptide attenuates Th2 response and stimulates Th1 activation and mucus adhesion promoting protein (MapA) as a cell-surface protein binds to mucus. This study evaluated the effect of HP-NAP and MapA conjugated with alumina nanoparticle on AR. HP-NAP and HP-NAP with MapA were conjugated to alumina nanoparticle and two separate nanoparticles were produced. The AR mice were treated with these and HP-NAP in peptide form. The AR symptoms, gene expression of mucus, levels of IL-33 and IL-4, and total and ovalbumin (OVA)-specific IgE levels were evaluated. Nasal rubbing, sneezing, gene expression of mucus, and IL-33 and IL-4 levels, and OVA-specific and total IgE were decreased in three treated groups compared to AR, and there was a significant decrease in the symptoms in AR-H-M-A group (P < 0.05) when compared to the other treated groups. HP-NAP has a controlling effect on AR, and in nanoparticle-conjugated form it can strongly attach to the airway's mucus via MapA. Therefore, cooperation of HP-NAP-alumina with MapA can produce an effective and applicable treatment for AR.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 过敏 4 区 免疫学
JCR分区:
出版当年[2023]版:
Q3 ALLERGY Q3 IMMUNOLOGY
最新[2023]版:
Q3 ALLERGY Q3 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China.
通讯作者:
通讯机构: [4]Department of Otolaryngology Division I, The First Affiliated Hospital of Kunming Medical University, Kunming, China [*1]Department of Otolaryngology Division I, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53661 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)